Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Turn TherapeuticsTTRX -5.09%11 3-1 Month Momentum % is 74.40% as of Sep. 13, 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,378 Biotechnology companies, Turn Therapeutics ranks better than 96.59% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-13), Turn Therapeutics's 3-1 Month Momentum % is 74.40%.
The industry rank for Turn Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
TTRX's 3-1 Month Momentum % is ranked better than 96.59% of 1378
companies
in the Biotechnology industry
Industry Median: 1.51
vs TTRX: 74.40
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Turn Therapeutics 3-1 Month Momentum % Related Terms
TTRX vs YDES, BCYC, FULC: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Turn Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Turn Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Turn Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Turn Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Turn Therapeutics (TTRX) has a 3-1 Month Momentum % of 74.40% as of Sep. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Turn Therapeutics and its competitors. According to the industry distribution chart, Turn Therapeutics ranks #47 out of 1378 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Turn Therapeutics' 3-1 Month Momentum % too high?
Turn Therapeutics' current 3-1 Month Momentum % is 74.40%. The Biotechnology industry median 3-1 Month Momentum % is 1.51. Turn Therapeutics' value of 74.40% is 4827.2% above this industry median. Based on the distribution chart, Turn Therapeutics ranks #47 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' 3-1 Month Momentum % compare to YDES and BCYC?
According to the Biotechnology industry distribution chart, Turn Therapeutics ranks #47 out of 1378 companies for 3-1 Month Momentum %. This places Turn Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.51. Turn Therapeutics' value of 74.40% is 4827.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.51, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Turn Therapeutics's current 3-1 Month Momentum % of 74.40% is 4827.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Turn Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Turn Therapeutics's current 3-1 Month Momentum % is 74.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current 3-1 Month Momentum % of 74.40%. The current 3-1 Month Momentum % is 74.40% and 4827.2% above the Biotechnology industry median of 1.51. Turn Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current 3-1 Month Momentum % is 74.40% as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score
Get the complete analysis for TTRX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TTRX has been successfully added to your 
